Diazoxide
Active ingredient · 2 therapeutic classes
Sold as PROGLYCEM
- Drug class
- Thiazide Derivatives
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 2
Overview
Diazoxide is an active pharmaceutical ingredient in the Thiazide Derivatives group (C02DA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 1 | April 30, 2025 |
| GB United Kingdom | MHRA | 1 | November 28, 2025 |
CACanada· Health Canada
1 product
Uses
PROGLYCEM (diazoxide) is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: • Adults: Inoperable islet cell adenoma or carcinoma or extrapancreatic malignancy. • Infants and Children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis.
PROGLYCEM may be used pre-operatively as a temporary measure and post-operatively if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established.
When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. 1 Pediatrics Pediatrics (birth – up to 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of PROGLYCEM in pediatric patients has been established.
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Diazoxide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00503347 · revised April 30, 2025
- [2]MHRA (UK) · PL363010021 · revised November 28, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.